Clinical efficacy of combination of pertuzumab, trastuzumab, and docetaxel for treatment of patients with HER2-positive breast cancer

Author:

Liu Yan-cui,Ma Ying,An Ning,Sun Ping,Wang Ying,Sun Cheng

Funder

National Natural Science Foundation of China

Research Project of Heilongjiang Provincial Health and Family Planning Commission

Research Project of Basic Scientific Research Expenses of Heilongjiang Provincial Higher Education Institutions

Project of Youth Academic Backone Program in Heilongjiang Institutions of Higher Learning

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference27 articles.

1. Indications for neoadjuvant systemic therapy for breast cancer;Gallagher;Adv Surg,2019

2. Epidemiological characteristics of and risk factors for breast cancer in the world;Momenimovahed;Breast Cancer (Dove Med Press),2019

3. Lifestyle intervention for breast cancer women;Hwang;J Lifestyle Med,2019

4. Optimal treatment of early stage HER2-positive breast cancer;Pernas;Cancer,2018

5. Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives;Soto-Perez-De-Celis;Expert Opin Investig Drugs,2018

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3